Table 1 patient characteristics at diagnosis of brain metastases and treatments
Patient and tumor characteristics | HER-2 negative patients | HER-2 positive patients not treated with trastuzumab | HER-2 positive patients treated with trastuzumab | Whole population | P value |
|---|---|---|---|---|---|
| Â | N = 78 | N = 20 | N = 32 | N = 130 | Â |
| Â | -60% | -15.38% | -24.62% | Â | Â |
Age at BM diagnosis (years)- median (range) | Â | Â | Â | Â | Â |
   < 65 years | 54(34-83) | 53 (33- 75) | 47(26-67) | 52(26-83) | 0.0178 |
   ≥ 65 years | 59/77 (76.62) | 15/20 (75) | 31/32 (96.88) | 105/129 (81.4) |  |
| Â | 18/77 (23.38) | 5/20 (25) | 1/32 (3.12) | 24/129 (18.6) | Â |
Karnofsky performance status | Â | Â | Â | Â | Â |
   < 70 | 32/76 (42.11) | 10/20 (50) | 6/31 (19.35) | 48/127 (37.8) | 0.0418 |
   ≥ 70 | 44/76 (57.89) | 10/20 (50) | 25/31 (80.65) | 79/127 (62.2) |  |
RTOG RPA class | 0 | 0 | 0 | 0 | 0.0391 |
   I | 43/75 (57.33) | 10/20 (50) | 25/31 (80.65) | 78/126 (61.9) |  |
   II | 32/75 (42.67) | 10/20 (50) | 6/31 (19.35) | 48/126 (38.1) |  |
   III |  |  |  |  |  |
Histology of primary BC | Â | Â | Â | Â | Â |
   Ductal | 70/76 (92.11) | 19/20 (95) | 30/32 (93.75) | 119/128 (92.97) | 0.5172** (ns) |
   Lobular | 2/76 (2.63) | 0 | 2/32 (6.25) | 4/128 (3.12) |  |
   Other | 4/76 (5.26) | 1/20 (5) | 0 | 5/128 (3.91) |  |
Histologic grade | Â | Â | Â | Â | Â |
   SBR I | 2/70 (2.86) | 1/17 (5.88) | 1/31 (3.23) | 4/118 (3.39) | 0.063** (ns) |
   SBR II | 27/70 (38.57) | 1/17 (5.88) | 11/31 (35.48) | 39/118 (33.05) |  |
   SBRIII | 41/70 (58.57) | 15/17 (88.24) | 19/31 (61.29) | 75/118 (63.56) |  |
Tumor HR status | Â | Â | Â | Â | Â |
   Positive | 48/76 (63.16) | 9/19 (47.37) | 17/32 (53.12) | 72/127 (56.69) | 0.1996 (ns) |
   Negative | 28/76 (36.84) | 10/19 (52.63) | 15/32 (46.88) | 55/127 (43.31) |  |
Number of BM | Â | Â | Â | Â | Â |
   Single | 6/78 (7.69) | 0 | 0 | 6/130 (4.62) | 0.1339** (ns) |
   Multiple | 72/78 (92.31) | 20/20 (100) | 32/32 (100) | 124/130 (95.38) | 0.1778 **(ns) |
   Meningitis | 17/77 (22.08) | 1/20 (5) | 4/31 (12.9) | 22/128 (17.19) |  |
   Yes | 60/77 (77.92) | 19/20 (95) | 27/31 (87.1) | 106/128 (82.81) |  |
   No |  |  |  |  |  |
Number of other metastatic sites | Â | Â | Â | Â | Â |
   0 (BM alone) | 6/78 (7.69) | 1/20 (5) | 0 | 7/130 (5.38) | 0.2971** (ns) |
   1 | 19/78 (24.36) | 3/20 (15) | 9/32 (28.12) | 31/130 (23.85) |  |
   2 | 20/78 (25.64) | 7/20 (35) | 14/32 (43.75) | 41/130 (31.54) |  |
   > 2 | 33/78 (42.31) | 9/20 (45) | 9/32 (28.12) | 51/130 (39.23) |  |
Concomitant and other metastases | Â | Â | Â | Â | Â |
   Liver | 35/78 (44.87) | 12/20 (60) | 23/32 (71.88) | 70/130 (53.85) | 0.0299 |
   Lung | 36/78 (46.15) | 11/20 (55) | 14/32 (43.75) | 61/130 (46.92) | 0.7147 (ns) |
   Bone | 51/78 (65.38) | 10/20 (50) | 18/32 (56.25) | 79/130 (60.77) | 0.3783 (ns) |
Previous chemotherapy | 55/78 (70.51) | 18/20 (90) | 32/32 (100) | 105/130 (80.77) | 0.0002** |
   Yes | 23/78 (29.49) | 2/20 (10) | 0 | 25/130 (19.23) |  |
   No |  |  |  |  |  |
Previous taxane-based chemotherapy | 36/78 (46.15) | 11/20 (55) | 25/31 (80.65) | 72/129 (55.81) | 0.0047 |
   Yes | 42/78 (53.85) | 9/20 (45) | 6/31 (19.35) | 57/129 (44.19) |  |
   No |  |  |  |  |  |
Lactate Deshydrogenase (LDH) | 35/61 (57.38) | 9/14 (64.29) | 13/19 (68.42) | 57/94 (60.64) | 0.6597 (ns) |
≤ 500 UI/L | 26/61 (42.62) | 5/14 (35.71) | 6/19 (31.58) | 37/94 (39.36) |  |
500 UI/L | 127-2088 | 120-3469 | 158-2199 | 120-3469 | Â |
range | Â | Â | Â | Â | Â |
Lymphocyte count | 25/70 (35.71) | 9/20 (45) | 3/20 (15) | 37/110 (33.64) | 0.1106 (ns) |
≤ 0.7 G/L | 45/70 (64.29) | 11/20 (55) | 17/20 (85) | 73/110 (66.36) |  |
> 0.7 G/L | 61-2285 | 40-1814 | 63-2050 | 40-2285 | Â |
range | Â | Â | Â | Â | Â |
Vital Status | 16/78 (20.51) | 2/20 (10) | 14/32 (43.75) 18/32 (56.25) | 32/130 (24.62) | 0.0138** |
alive | 62/78 (79.49) | 18/20 (90) | Â | 98/130 (75.38) | Â |
dead | Â | Â | Â | Â | Â |